| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Cholecalciferol (Vitamin D3; Colecalciferol), a secosteroid (a steroid molecule with one ring open), is a naturally occurring form of vitamin D. When it is metabolically activated, cholecalciferol transforms into 1,25-dihydroxy vitamin D3, the active form that promotes cell differentiation and inhibits the growth of cancer cells. A steroid hormone called vitamin D3/cholecalciferol is created in the skin in response to UV light exposure or is acquired through diet. 1,25-dihydroxycholecalciferol, the active form of cholecalciferol, is crucial for preserving blood calcium and phosphorus levels as well as bone mineralization. Cholecalciferol that has been activated binds to vitamin D receptors and changes the expression of certain genes.
| ln Vitro |
Vitamin D3 is an in vivo inactive molecule of vitamin D. To activate vitamin D3, it goes through two hydroxylation processes. The enzyme 25-hydroxylase (CYP27A1) and possibly other enzymes (such as CYP2R1) hydroxylate vitamin D3 in the liver to create the circulating prohormone 25-hydroxy vitamin D3 [25(OH)D3][1].
The kidneys use the enzyme 1-alpha-hydroxylase to carry out the second hydroxylation, resulting in 1,25-dihydroxycholecalciferol, or calcitriol, the biologically active form of vitamin D[1].
Vitamin D3 (2-10 μM; 24-48 hours) shows effects against proliferation that are dependent on both time and dose. After treating with 10 μM vitamin D3, the viability of 62% (IK), 52% (RL-95-2), and 55% (Hec-1A) is at its lowest point after 72 hours. However, there is no discernible decrease in viable cells after a 24-hour exposure[2].
Cholecalciferol (10 μM; 24-48 hours) exhibits notable increases in nuclear VDR staining and causes IK cells to become activated locally for VDR[1].
|
|---|---|
| ln Vivo |
Cholecalciferol (oral gavage; 5 mg/kg; 7 days) increases the toxicity of CCl4 exclusively in the liver, as shown by elevated plasma levels of ALT and AST, two biochemical indicators of hepatic injury. Although renal calcium content does not significantly differ between mice, it significantly raises renal calcium levels in mice[3].
|
| Animal Protocol |
Male ddY mice on CCl4 toxicity[3]
5 mg/kg Oral gavage; 5 mg/kg; 7 days |
| References |
| Molecular Formula |
C27H44O
|
|---|---|
| Molecular Weight |
384.6377
|
| Exact Mass |
384.34
|
| Elemental Analysis |
C, 84.31; H, 11.53; O, 4.16
|
| CAS # |
67-97-0
|
| Related CAS # |
Vitamin D3-d7;1627523-19-6;3-epi-Vitamin D3;57651-82-8;Vitamin D3-13C3;Vitamin D3-d3;80666-48-4;Vitamin D3-13C5
|
| Appearance |
White to off-white solid powder
|
| SMILES |
C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
|
| InChi Key |
QYSXJUFSXHHAJI-YRZJJWOYSA-N
|
| InChi Code |
InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
|
| Chemical Name |
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
|
| Synonyms |
Activated 7-dehydrocholesterol; Cholecalciferol; Calciol; Vitamin D3; Colecalciferol; Arachitol; Ricketon; Trivitan; Vigorsan; Deparal; Vigantol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~259.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (5.41 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5998 mL | 12.9992 mL | 25.9983 mL | |
| 5 mM | 0.5200 mL | 2.5998 mL | 5.1997 mL | |
| 10 mM | 0.2600 mL | 1.2999 mL | 2.5998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05613192 | Recruiting | Drug: Cholecalciferol | Non-Alcoholic Fatty Liver Disease |
Ain Shams University | October 31, 2022 | Phase 3 |
| NCT03613116 | Recruiting | Dietary Supplement: Vitamin D3 | Vitamin D Deficiency Cognitive Decline |
University of California, Davis | March 18, 2019 | Phase 2 |
| NCT04229368 | Recruiting | Dietary Supplement: Vitamin D3 | Hip Arthropathy Knee Arthropathy |
Brigham and Women's Hospital | September 1, 2019 | Not Applicable |
| NCT05586529 | Recruiting | Dietary Supplement: Cholecalciferol |
Hypocalcemia | Pak Emirates Military Hospital | November 1, 2022 | Not Applicable |
| NCT06054919 | Active Recruiting |
Drug: Cholecalciferol | Vitamin D Deficiency | Indonesia University | April 1, 2021 | Phase 2 Phase 3 |
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
